Summit Therapeutics is trading 7.53% up today at $15.70 after partner Akeso reported statistically significant, clinically meaningful overall-survival benefits for ivonescimab versus pembrolizumab in the Phase III HARMONi-2 trial.
- The September 2, 2026 announcement followed a prespecified interim analysis assessed by an independent monitoring committee; detailed numerical survival results were not released.
- XBI is up 2.75%, while broader indexes are modestly higher; the company-specific trial catalyst remains the primary explanation.